Joseph Thome
Stock Analyst
(n/a)
# 4,647
Out of 4,655 analysts
23
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNS Marinus Pharmaceuticals | Downgrades: Hold | n/a | $0.33 | - | 2 | Oct 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $374.02 | +6.95% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $24.62 | - | 1 | Jul 2, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | n/a | $2.79 | - | 2 | Jun 18, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $26.47 | +28.45% | 1 | Jun 17, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $90 | $86.54 | +4.00% | 2 | Apr 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.03 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi | Initiates: Outperform | n/a | $2.11 | - | 1 | Mar 5, 2024 | |
| PTCT PTC Therapeutics | Maintains: Market Perform | $32 → $30 | $40.47 | -25.87% | 2 | Mar 1, 2024 | |
| YMAB Y-mAbs Therapeutics | Downgrades: Market Perform | n/a | $14.74 | - | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.69 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.01 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.33 | - | 1 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $88.84 | +46.33% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.81 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.60 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.27 | - | 1 | Jul 15, 2021 |
Marinus Pharmaceuticals
Oct 25, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.33
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $374.02
Upside: +6.95%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $24.62
Upside: -
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.79
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $26.47
Upside: +28.45%
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Buy
Price Target: $80 → $90
Current: $86.54
Upside: +4.00%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.03
Upside: -
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.11
Upside: -
PTC Therapeutics
Mar 1, 2024
Maintains: Market Perform
Price Target: $32 → $30
Current: $40.47
Upside: -25.87%
Y-mAbs Therapeutics
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.74
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.69
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.01
Upside: -
Oct 10, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.33
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $88.84
Upside: +46.33%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.81
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $17.60
Upside: -
Jul 15, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.27
Upside: -